Ingevity Poised to Cut Emissions Following Solar Power Deal With NextEra — Energy Comment
By Jennifer Tershak
Ingevity's agreement to buy solar power from a subsidiary of NextEra Energy Resources will allow the company to receive and retire renewable energy credits and offset a significant portion of its Scope 2 emissions produced at their U.S. manufacturing locations.
On carbon neutrality:
The manufacturer of specialty chemicals and carbon materials is looking to reduce greenhouse gas emissions and wants to be carbon neutral for absolute GHG emissions from manufacturing operations by 2050. "Collaborating with NextEra Energy Resources for the development of a solar facility in a location in the U.S. with high electricity demands to create renewably-sourced energy is a natural extension of our sustainability profile and an important element in our effort to achieve carbon neutrality for the benefit of our operations and the industries that rely on our products to advance their own sustainability goals," Ingevity's Chief Executive Officer John Fortson said.
On the solar facility:
Ingevity will receive 85 megawatts of capacity at a new NextEra Energy Resources solar site to be constructed in North Texas. Ingevity will also receive and retire renewable energy credits to offset a significant portion of its Scope 2 emissions from U.S. manufacturing locations and advance the company toward its 2050 target. The solar facility is expected to be fully operational by the end of 2025.
Write to Jennifer Tershak at jennifer.tershak@wsj.com
(END) Dow Jones Newswires
August 15, 2023 11:58 ET (15:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How the Tokyo Stock Exchange Is Pushing for Better Capital Allocation
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting